TIBET PHARMA(600211)2024-10-29 07:47Financial Performance - The company's operating revenue for Q3 2024 was ¥560,745,616.61, representing a decrease of 8.13% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2024 was ¥168,730,194.25, a decline of 34.96% year-on-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 7.70% to ¥162,992,984.36 for the current period[2]. - The basic earnings per share for the year-to-date period was ¥0.53, a decrease of 34.15%[2]. - The weighted average return on equity for Q3 2024 was 4.69%, down by 3.00 percentage points year-on-year[2]. - Total operating revenue for the first three quarters of 2024 was CNY 2,175,443,351.59, a decrease of 8.13% compared to CNY 2,368,009,918.39 in the same period of 2023[16]. - Net profit attributable to shareholders of the parent company for the first three quarters of 2024 was CNY 791,866,935.56, a decrease of 7.41% from CNY 855,341,904.01 in 2023[17]. - The company reported a net profit of CNY 795,146,775.01 for the first three quarters of 2024, down 7.89% from CNY 863,520,088.44 in the same period of 2023[17]. - The company reported a basic earnings per share of CNY 2.46 for the first three quarters of 2024, down from CNY 2.65 in 2023[18]. - The company achieved a gross profit margin of approximately 96.6% in the first three quarters of 2024, compared to 96.3% in the same period of 2023[23]. Cash Flow and Investments - The net cash flow from operating activities for Q3 2024 was ¥152,550,739.38, down 36.02% compared to the previous year[2]. - The company reported a significant reduction in employee compensation payable, decreasing to ¥17,659,620.57 from ¥39,051,842.22, a drop of approximately 54.80%[14]. - The cash flow from operating activities for the first three quarters of 2024 was ¥535,557,687.15, slightly down from ¥563,510,846.90 in the same period of 2023[27]. - The company reported a net cash outflow from investing activities of ¥103,171,568.03 in 2024, contrasting with a net inflow of ¥11,724,402.35 in 2023[27]. - The total cash inflow from investment activities in the first three quarters of 2024 was CNY 3,577,250,394.80, significantly higher than CNY 2,171,462,711.38 in 2023, marking an increase of 64.5%[20]. - The net cash flow from investment activities for the first three quarters of 2024 was CNY 171,076,071.56, recovering from a negative cash flow of CNY -316,412,075.57 in the same period of 2023[20]. - The total cash outflow from financing activities in the first three quarters of 2024 was CNY 1,050,332,572.98, compared to CNY 827,425,124.64 in 2023, indicating an increase of 27%[20]. Assets and Liabilities - The total assets at the end of the reporting period were ¥4,671,034,014.20, an increase of 1.82% from the end of the previous year[3]. - The total liabilities of the company as of the end of the third quarter of 2024 were CNY 1,007,308,783.65, a decrease from CNY 1,213,736,396.92 at the end of 2023[15]. - The total assets of the company as of the end of the third quarter of 2024 were CNY 4,671,034,014.20, an increase from CNY 4,587,357,109.81 at the end of 2023[15]. - The total current assets increased to CNY 2,560,464,115.96 in Q3 2024, compared to CNY 2,171,480,587.74 in the previous year, representing a growth of 17.9%[22]. - The total liabilities as of the end of the third quarter of 2024 amounted to ¥763,339,811.85, compared to ¥670,240,257.80 at the end of the third quarter of 2023, indicating an increase of 13.9%[23]. Shareholder Information - The company distributed cash dividends of ¥0.737 per share, totaling ¥182,730,190.29, and increased the total share capital by 74,381,353 shares[4]. - The total number of ordinary shareholders at the end of the reporting period was 43,917[8]. - The total equity attributable to shareholders of the parent company increased to CNY 3,629,963,702.70 in 2024, up from CNY 3,344,589,024.49 in 2023[15]. - The total equity increased to ¥4,007,532,852.12 in 2024 from ¥3,690,374,750.89 in 2023, reflecting an increase of 8.6%[23]. Research and Development - Research and development expenses increased to CNY 17,025,333.28 in 2024, up 104.00% from CNY 8,319,437.14 in 2023[16]. - Research and development expenses increased to ¥11,671,655.25 in 2024 from ¥8,231,916.12 in 2023, marking a 42.4% rise[23]. Wealth Management and Financial Strategy - The company reported a total cash management amount of RMB 1,030 million, with an unexpired balance of RMB 690 million[10]. - The company has invested in bank wealth management products, with a total of RMB 2,000 million in various financial products, yielding annualized returns between 1.1% and 2.50%[11]. - The company has engaged in fixed income and money market investments, with a total of RMB 4,000 million in various bank financial products[11]. - The company has no overdue amounts in its cash management activities, indicating effective liquidity management[10]. - The company has a consistent strategy of utilizing idle funds for wealth management, enhancing overall financial performance[10]. - The company has maintained a diversified investment approach across multiple banks, ensuring risk mitigation[11]. - The company has established agreements with banks for wealth management, ensuring predictable returns[11]. - The company has not indicated any restricted situations in its financial management activities, reflecting operational flexibility[11]. - The company has a clear plan for future wealth management activities, indicating ongoing financial strategy development[11].